Home Cytoskeletal Signaling HSP (HSP90) inhibitor - Apoptosis related activator Ganetespib (STA-9090) For research use only.

Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Ganetespib (STA-9090) Chemical Structure

Ganetespib (STA-9090) Chemical Structure

CAS No. 888216-25-9

Purity & Quality Control

Ganetespib (STA-9090) Related Products

Signaling Pathway

HSP (HSP90) Signaling Pathways

HSP (HSP90) Signaling Pathway

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H1975 Growth Inhibition Assay 72 h IC50=8 nM 22144665
NCI-H1975 Growth Inhibition Assay 48 h IC50=16 nM 22144665
Calu-6 Growth Inhibition Assay IC50=64 nM 23012248
Calu-1 Growth Inhibition Assay IC50=58 nM 23012248
H2122 Growth Inhibition Assay IC50=53 nM 23012248
A549 Growth Inhibition Assay IC50=43 nM 23012248
H358 Growth Inhibition Assay IC50=29 nM 23012248
H1734 Growth Inhibition Assay IC50=28 nM 23012248
H727 Growth Inhibition Assay IC50=28 nM 23012248
COR-L23 Growth Inhibition Assay IC50=22 nM 23012248
H1792 Growth Inhibition Assay IC50=20 nM 23012248
H2009 Growth Inhibition Assay IC50=19 nM 23012248
SK-LU-1 Growth Inhibition Assay IC50=18 nM 23012248
H2212 Growth Inhibition Assay IC50=17 nM 23012248
H441 Growth Inhibition Assay IC50=14 nM 23012248
H2030 Growth Inhibition Assay IC50=12 nM 23012248
H23 Growth Inhibition Assay IC50=11 nM 23012248
HOP-62 Growth Inhibition Assay IC50=11 nM 23012248
IA-LM Growth Inhibition Assay IC50=10 nM 23012248
H460 Growth Inhibition Assay IC50=8 nM 23012248
H157 Growth Inhibition Assay IC50=7 nM 23012248
H1355 Growth Inhibition Assay IC50=5 nM 23012248
VCaP Growth Inhibition Assay IC50=7 nM 23152004
LNCaP Growth Inhibition Assay IC50=8 nM 23152004
Ramos-RA1 Growth Inhibition Assay IC50=7.4 nM 23303741
Karpas-299 Growth Inhibition Assay IC50=9.6 nM 23303741
Kasumi-1 Growth Inhibition Assay IC50=5.8 nM 23303741
CCRF-CEM (2) Growth Inhibition Assay IC50=7.2 nM 23303741
CCRF-CEM (1) Growth Inhibition Assay IC50=12.5 nM 23303741
MOLT-4 Growth Inhibition Assay IC50=10.6 nM 23303741
RS4;11 Growth Inhibition Assay IC50=13.5 nM 23303741
COG-LL-317 Growth Inhibition Assay IC50=4.4 nM 23303741
NALM-6 Growth Inhibition Assay IC50=11.7 nM 23303741
CHLA-136 Growth Inhibition Assay IC50=23.2 nM 23303741
CHLA-90 Growth Inhibition Assay IC50=22.3 nM 23303741
NB-EBc1 Growth Inhibition Assay IC50=16.8 nM 23303741
NB-1643 Growth Inhibition Assay IC50=7.4 nM 23303741
SJ-GBM2 Growth Inhibition Assay IC50=12.9 nM 23303741
CHLA-258 Growth Inhibition Assay IC50=6.4 nM 23303741
CHLA-10 Growth Inhibition Assay IC50=5.7 nM 23303741
CHLA-9 Growth Inhibition Assay IC50=4.6 nM 23303741
TC-71 Growth Inhibition Assay IC50=4.5 nM 23303741
CHLA-266 Growth Inhibition Assay IC50=27.1 nM 23303741
BT-12 Growth Inhibition Assay IC50=14.3 nM 23303741
Rh30 Growth Inhibition Assay IC50=5.6 nM 23303741
Rh18 Growth Inhibition Assay IC50=6.2 nM 23303741
Rh41 Growth Inhibition Assay IC50=10.4 nM 23303741
RD Growth Inhibition Assay IC50=8 nM 23303741
K033 Apoptosis Assay 100 nM 72 h significantly induces apoptosis 23418523
M23 Apoptosis Assay 100 nM 72 h significantly induces apoptosis 23418523
K029 Apoptosis Assay 100 nM 72 h significantly induces apoptosis 23418523
K028 Apoptosis Assay 100 nM 72 h significantly induces apoptosis 23418523
K008 Apoptosis Assay 100 nM 72 h significantly induces apoptosis 23418523
K033 Function Assay 250 nM 24 h induces a modest increase in G1 population 23418523
M23 Function Assay 250 nM 24 h induces G1 and G2/M arrest 23418523
K029 Function Assay 250 nM 24 h induces G1 arrest 23418523
K028 Function Assay 250 nM 24 h induces G2 arrest 23418523
K008 Function Assay 250 nM 24 h induces G2 arrest 23418523
K033 Cell Viability Assay IC50=75.5 nM 23418523
M23 Cell Viability Assay IC50=37.5 nM 23418523
K029 Cell Viability Assay IC50=46 nM 23418523
K028 Cell Viability Assay IC50=84 nM 23418523
K008 Cell Viability Assay IC50=60 nM 23418523
H3122 Cell Viability Assay 0-1000 nM 72 h IC50=10 nM 23533265
H2228 Cell Viability Assay 0-1000 nM 72 h IC50=13 nM 23533265
A1847 Apoptosis Assay 10-100 nM 24/48/72 h induces apoptosis time and dose dependently 23900136
OVCAR-8 Apoptosis Assay 10-100 nM 24/48/72 h induces apoptosis time and dose dependently 23900136
OVCAR-5 Apoptosis Assay 10-100 nM 24/48/72 h induces apoptosis time and dose dependently 23900136
SKOV-3 Cell Viability Assay 0-1000 nM 72 h inhibits cell viability dose dependently 23900136
A1847 Cell Viability Assay 0-1000 nM 72 h inhibits cell viability dose dependently 23900136
OVCAR-8 Cell Viability Assay 0-1000 nM 72 h inhibits cell viability dose dependently 23900136
OVCAR-5 Cell Viability Assay 0-1000 nM 72 h inhibits cell viability dose dependently 23900136
H146  Function Assay 30 nM 72 h induces persistent G2/M phase arrest 24166505
GLC4 Function Assay 30 nM 72 h induces persistent G2/M phase arrest 24166505
H82 Function Assay 30 nM 72 h induces persistent G2/M phase arrest 24166505
AC3 Growth Inhibition Assay IC50=25.9 nM 24166505
H1173 Growth Inhibition Assay IC50=12.62 nM 24166505
H792 Growth Inhibition Assay IC50=45.07 nM 24166505
H620 Growth Inhibition Assay IC50=32.67 nM 24166505
N592 Growth Inhibition Assay IC50=14.12 nM 24166505
H526 Growth Inhibition Assay IC50=21.64 nM 24166505
H187 Growth Inhibition Assay IC50=24.99 nM 24166505
H146 Growth Inhibition Assay IC50=28.51 nM 24166505
H128 Growth Inhibition Assay IC50=69.55 nM 24166505
H69 Growth Inhibition Assay IC50=83.36 nM 24166505
GLC4 Growth Inhibition Assay IC50=20.47 nM 24166505
H82 Growth Inhibition Assay IC50=30.27 nM 24166505
MDA-MB-231 Function Assay 100 nM 24 h inhibits the migratory and invasive capacity  24173541
BT-20  Function Assay 100/250 nM 24 h resulted in a dose-dependent destabilization of EGFR, IGF-IR, MET, and CRAF 24173541
MDA-MB-435 Function Assay 100 nM 30 min inhibits accumulation of HIF-1α 24248265
MDA-MB-231 Function Assay 100 nM 30 min inhibits accumulation of HIF-1α 24248265
HCC2998 Growth Inhibition Assay IC50=128 nM 24682747
SK-CO-1 Growth Inhibition Assay IC50=81 nM 24682747
LS-123 Growth Inhibition Assay IC50=73 nM 24682747
SNU-C2B Growth Inhibition Assay IC50=45 nM 24682747
LS-1034 Growth Inhibition Assay IC50=31 nM 24682747
LoVo Growth Inhibition Assay IC50=22 nM 24682747
COLO-678 Growth Inhibition Assay IC50=21 nM 24682747
NCI-H747 Growth Inhibition Assay IC50=17 nM 24682747
COLO-205 Growth Inhibition Assay IC50=14 nM 24682747
HCT 116 Growth Inhibition Assay IC50=14 nM 24682747
HuTu-80 Growth Inhibition Assay IC50=13 nM 24682747
HCT-15 Growth Inhibition Assay IC50=8 nM 24682747
SW620 Growth Inhibition Assay IC50=8 nM 24682747
LS-411 N Growth Inhibition Assay IC50=5 nM 24682747
RKO Growth Inhibition Assay IC50=4 nM 24682747
SW780 Growth Inhibition Assay IC50=3451 nM 24784839
RT4 Growth Inhibition Assay IC50=1733 nM 24784839
TCCSUP Growth Inhibition Assay IC50=142 nM 24784839
MGH-U3 Growth Inhibition Assay IC50=53 nM 24784839
HT-1197 Growth Inhibition Assay IC50=53 nM 24784839
5637 Growth Inhibition Assay IC50=44 nM 24784839
35612 Growth Inhibition Assay IC50=38 nM 24784839
KU-19-19 Growth Inhibition Assay IC50=36 nM 24784839
LB831-BLC Growth Inhibition Assay IC50=34 nM 24784839
UM-UC3 Growth Inhibition Assay IC50=33 nM 24784839
647-V Growth Inhibition Assay IC50=27 nM 24784839
HT-1376 Growth Inhibition Assay IC50=21 nM 24784839
J82 Growth Inhibition Assay IC50=18 nM 24784839
BFTC Growth Inhibition Assay IC50=17 nM 24784839
SCaBER Growth Inhibition Assay IC50=10 nM 24784839
639-V Growth Inhibition Assay IC50=10 nM 24784839
RT112 Growth Inhibition Assay IC50=9 nM 24784839
T24 Growth Inhibition Assay IC50=7 nM 24784839
SW-1710 Growth Inhibition Assay IC50=6 nM 24784839
DSH1 Growth Inhibition Assay IC50=6 nM 24784839
CAL27 Cytoxicity Assay 10/50 nM 24 h decreases cell proliferation dose dependently 25205430
Detroit562 Cytoxicity Assay 10/50 nM 24 h decreases cell proliferation dose dependently 25205430
FUDA Cytoxicity Assay 10/50 nM 24 h decreases cell proliferation dose dependently 25205430
SCC25 Cytoxicity Assay 10/50 nM 24 h decreases cell proliferation dose dependently 25205430
HT-29 Function Assay 50nM 24 h DMSO induced G0/G1 arrest 25210794
HCT-116 Function Assay 50nM 24 h DMSO induced G0/G1 arrest 25210794
MGC-803 Function Assay 0.1-1000 nM 24 h induces G2/M cell-cycle arrest 25590805
MKN-28 Cell Viability Assay 0.1-1000 nM 72 h inhibits cell viability dose dependently 25590805
SGC-7901 Cell Viability Assay 0.1-1000 nM 72 h inhibits cell viability dose dependently 25590805
MGC-803 Cell Viability Assay 0.1-1000 nM 72 h inhibits cell viability dose dependently 25590805
MV411 Apoptosis Assay 30/80/150/250 nM 24/48/72 h induces dose dependant induction of apoptosis 25882550
HL60 Apoptosis Assay 30/80/150/250 nM 24/48/72 h induces dose dependant induction of apoptosis 25882550
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells 29435139
Click to View More Cell Line Experimental Data

Biological Activity

Description Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Targets
HSP90 [1]
(OSA 8 cells)
4 nM
In vitro
In vitro The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. [1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. [1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. [2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. [3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. [4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.[4]
Cell Research Cell lines OSA cells
Concentrations 0.001-1μM
Incubation Time 5 days
Method A total of 1.5 × 103 OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.
Experimental Result Images Methods Biomarkers Images PMID
Western blot EGFR / c-Met / IGF-1Rβ/ Akt / p-Akt / ERK / p-ERK p27(Kip1) / p21 (Cip1) / Cyclin D1 / Cyclin E / Cyclin B1 / CDK1 / CDK2 / CDK4 Survivin / Bcl-2 / Bcl-xl / Mcl-1 B-RAF / C-RAF / N-RAS HER2 / p-STAT3 / BIM CDK1 / Cyclin D1 / Cyclin B1 / p27 c-PARP / c-caspase 3 / caspase 8 / c-caspase 8 / caspase 9 / c-caspase 9 ErbB2 / pErbB2 / Src / pSrc / mTOR / pmTOR / Bad / pBad / GSK3 / pGSK3 Wee1 / p-Wee1 / Chk1 / p-Chk1 23418523
Growth inhibition assay Cell viability 23418523
In Vivo
In vivo Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.[4]
Animal Research Animal Models Female severe combined immune-deficient (SCID) mice
Dosages 25 mg/kg/day for 3 days
Administration Tail vein injection
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02192541 Terminated
Neoplasms
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
 December 2 2014 Phase 1
NCT02008877 Completed
Malignant Peripheral Nerve Sheath Tumors (MPNST)|Sarcoma
Sarcoma Alliance for Research through Collaboration|Synta Pharmaceuticals Corp.|United States Department of Defense
 December 2013 Phase 1|Phase 2

Chemical Information & Solubility

Molecular Weight 364.4 Formula

C20H20N4O3
CAS No. 888216-25-9 SDF Download Ganetespib (STA-9090) SDF
Smiles CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)O
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 40 mg/mL ( (109.76 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 9 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Does this inhibitor inhibit both isoforms of HSP90?

Answer:
We don't have the information now and it is not very clear in the literature either. From following two references, it indicates that Ganetespib might be specific to the alpha form “Ganetespib binds to the ATP binding site of Hsp90 alpha with a Kd of 110 nM” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477583/

Tags: buy Ganetespib (STA-9090) | Ganetespib (STA-9090) supplier | purchase Ganetespib (STA-9090) | Ganetespib (STA-9090) cost | Ganetespib (STA-9090) manufacturer | order Ganetespib (STA-9090) | Ganetespib (STA-9090) distributor